Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017227033> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2017227033 endingPage "541" @default.
- W2017227033 startingPage "541" @default.
- W2017227033 abstract "The EORTC 08062 phase II randomised trial investigated the activity and safety of single agent amrubicin, cisplatin combined with amrubicin, and cisplatin combined with etoposide as first line treatment in extensive disease (ED) small cell lung cancer (SCLC).Eligible patients with previously untreated ED-SCLC, WHO performance status (PS) 0–2 and measurable disease were randomised to 3 weekly cycles of either amrubicin alone 45 mg/m2 i.v. day(d) 1–3 (A), cisplatin 60 mg/m2 i.v. d1 and amrubicin 40 mg/m2 i.v. d1–3 (PA), or cisplatin 75 mg/m2 i.v. d1 and etoposide 100 mg/m2 d1, d2–3 i.v./po (PE). The primary end-point was overall response rate (ORR) as assessed by local investigators (RECIST1.0 criteria). Secondary end-points were treatment toxicity, progression-free survival and overall survival.The number of randomised/eligible patients who started treatment was 33/28 in A, 33/30 in PA and 33/30 in PE, respectively. Grade (G) ⩾3 haematological toxicity in A, PA and PE was neutropenia (73%, 73%, 69%); thrombocytopenia (17%, 15%, 9.4%), anaemia (10%, 15%, 3.1%) and febrile neutropenia (13%, 18%, 6%). Early deaths, including treatment related, occurred in 1, 3 and 3 patients in A, PA and PE arms, respectively. Cardiac toxicity did not differ among the 3 arms. Out of 88 eligible patients who started treatment, ORR was 61%, (90% 1-sided confidence intervals [CI] 47–100%), 77% (CI 64–100%) and 63%, (CI 50–100%) for A, PA and PE respectively.All regimens were active and PA met the criteria for further investigation, despite slightly higher haematological toxicity." @default.
- W2017227033 created "2016-06-24" @default.
- W2017227033 creator A5018054038 @default.
- W2017227033 creator A5019357584 @default.
- W2017227033 creator A5019588157 @default.
- W2017227033 creator A5049504224 @default.
- W2017227033 creator A5049991634 @default.
- W2017227033 creator A5051698935 @default.
- W2017227033 creator A5055972238 @default.
- W2017227033 creator A5066084910 @default.
- W2017227033 creator A5069095893 @default.
- W2017227033 creator A5090069473 @default.
- W2017227033 date "2009-09-01" @default.
- W2017227033 modified "2023-10-14" @default.
- W2017227033 title "9121 Amrubicin monotherapy in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: final results of a phase 2 trial" @default.
- W2017227033 doi "https://doi.org/10.1016/s1359-6349(09)71834-8" @default.
- W2017227033 hasPublicationYear "2009" @default.
- W2017227033 type Work @default.
- W2017227033 sameAs 2017227033 @default.
- W2017227033 citedByCount "0" @default.
- W2017227033 crossrefType "journal-article" @default.
- W2017227033 hasAuthorship W2017227033A5018054038 @default.
- W2017227033 hasAuthorship W2017227033A5019357584 @default.
- W2017227033 hasAuthorship W2017227033A5019588157 @default.
- W2017227033 hasAuthorship W2017227033A5049504224 @default.
- W2017227033 hasAuthorship W2017227033A5049991634 @default.
- W2017227033 hasAuthorship W2017227033A5051698935 @default.
- W2017227033 hasAuthorship W2017227033A5055972238 @default.
- W2017227033 hasAuthorship W2017227033A5066084910 @default.
- W2017227033 hasAuthorship W2017227033A5069095893 @default.
- W2017227033 hasAuthorship W2017227033A5090069473 @default.
- W2017227033 hasConcept C126322002 @default.
- W2017227033 hasConcept C141071460 @default.
- W2017227033 hasConcept C203092338 @default.
- W2017227033 hasConcept C2776256026 @default.
- W2017227033 hasConcept C2776694085 @default.
- W2017227033 hasConcept C2777063308 @default.
- W2017227033 hasConcept C2778119113 @default.
- W2017227033 hasConcept C2778850193 @default.
- W2017227033 hasConcept C535046627 @default.
- W2017227033 hasConcept C71924100 @default.
- W2017227033 hasConcept C90924648 @default.
- W2017227033 hasConceptScore W2017227033C126322002 @default.
- W2017227033 hasConceptScore W2017227033C141071460 @default.
- W2017227033 hasConceptScore W2017227033C203092338 @default.
- W2017227033 hasConceptScore W2017227033C2776256026 @default.
- W2017227033 hasConceptScore W2017227033C2776694085 @default.
- W2017227033 hasConceptScore W2017227033C2777063308 @default.
- W2017227033 hasConceptScore W2017227033C2778119113 @default.
- W2017227033 hasConceptScore W2017227033C2778850193 @default.
- W2017227033 hasConceptScore W2017227033C535046627 @default.
- W2017227033 hasConceptScore W2017227033C71924100 @default.
- W2017227033 hasConceptScore W2017227033C90924648 @default.
- W2017227033 hasIssue "2" @default.
- W2017227033 hasLocation W20172270331 @default.
- W2017227033 hasOpenAccess W2017227033 @default.
- W2017227033 hasPrimaryLocation W20172270331 @default.
- W2017227033 hasRelatedWork W2003291927 @default.
- W2017227033 hasRelatedWork W2018507611 @default.
- W2017227033 hasRelatedWork W2052930651 @default.
- W2017227033 hasRelatedWork W2073623993 @default.
- W2017227033 hasRelatedWork W2077567025 @default.
- W2017227033 hasRelatedWork W2243956249 @default.
- W2017227033 hasRelatedWork W2253280322 @default.
- W2017227033 hasRelatedWork W2292524166 @default.
- W2017227033 hasRelatedWork W2428528889 @default.
- W2017227033 hasRelatedWork W2609842262 @default.
- W2017227033 hasVolume "7" @default.
- W2017227033 isParatext "false" @default.
- W2017227033 isRetracted "false" @default.
- W2017227033 magId "2017227033" @default.
- W2017227033 workType "article" @default.